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Amelioration of proteolipid protein 139 –151-induced
encephalomyelitis in SJL mice by modified amino acid
copolymers and their mechanisms
Joel N. H. Stern†‡, Zsolt Illés‡§, Jayagopala Reddy§, Derin B. Keskin†, Eric Sheu†, Masha Fridkis-Hareli†,
Hiroyuki Nishimura†, Celia F. Brosnan¶, Laura Santambrogio储, Vijay K. Kuchroo§**, and Jack L. Strominger†储**††
†Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138; §Center for Neurologic Diseases, Harvard Institute of Medicine,
Boston, MA 02115; 储Department of Cancer Immunology and AIDS, Dana–Farber Cancer Institute, Boston, MA 02115; and ¶Department of Pathology, Albert
Einstein College of Medicine, Bronx, NY 10461

Copolymer 1 [Cop1, glatiramer acetate, Copaxone, poly(Y,E,A,K)n]
is widely used in the treatment of relapsing兾remitting multiple
sclerosis in which it reduces the frequency of relapses by ⬇30%. In
the present study, copolymers with modified amino acid compositions (based on the binding motif of myelin basic protein 85–99
to HLA-DR2) have been developed with the aim of suppressing
multiple sclerosis more effectively. The enhanced efficacy of these
copolymers in experimental autoimmune encephalomyelitis (EAE)
induced in SJL兾J mice with proteolipid protein 139 –151 was demonstrated by using three protocols: (i) simultaneous administration
of autoantigen and copolymer (termed prevention), (ii) pretreatment with copolymers (vaccination), or (iii) administration of
copolymers after disease onset (treatment). Strikingly, in the
treatment protocol administration of soluble VWAK and FYAK
after onset of disease led to stasis of its progression and suppression of histopathological evidence of EAE. The mechanisms by
which these effects are achieved have been examined in several
types of assays: binding of copolymers to I-As in competition with
proteolipid protein 139 –151 (blocking), cytokine production by T
cells (T helper 2 polarization), and transfer of protection by CD3ⴙ
splenocytes or, notably, by copolymer-specific T cell lines (induction of regulatory T cells). The generation of these copolymerspecific regulatory T cells that secrete IL-4 and IL-10 and are
independent of the immunizing autoantigen is very prominent
among the multiple mechanisms that account for the observed
suppressive effect of copolymers in EAE.
multiple sclerosis 兩 cytokines 兩 peptides 兩 T cells 兩 autoimmunity

M

ultiple sclerosis (MS) is a chronic inflammatory disease of
the central nervous system affecting young adults. In Northern European Caucasian MS patients, the disease is strongly
associated with the HLA-DR2 (DRA兾DRB1*1501) haplotype
(1–3). Experimental autoimmune encephalomyelitis (EAE), an
animal model for MS, can be induced in mice by administration of
peptides derived from myelin proteins, i.e., proteolipid protein
(PLP) 139–151 (4), myelin oligodendrocyte glycoprotein 35–55 (5),
or myelin basic protein (MBP) 85–99 (6–8). In this model, selfreactive CD4⫹ T cells produce IFN-␥, a T helper (Th)-1 cytokine,
that is believed to mediate the disease (9), whereas Th2 cells and
cytokines, namely IL-4 and IL-10, have been shown to reduce its
severity (10, 11).
Various therapeutic strategies involving agents that compete
with the process of recognition of HLA-DR2 (DRA兾
DRB1*1501)兾MBP85–99 complexes by autoreactive T cells have
been attempted in MS. Agents such as copolymers, peptides,
oligomers, altered peptide ligands, and peptide antigens have been
used for this purpose, and of these Copolymer 1 (Cop1) is currently
widely used in the treatment of MS (12–21). Cop1 is a random
amino acid copolymer of L-tyrosine (Y), L-glutamic acid (E),
L-alanine (A), and L-lysine (K), in a molar ratio of ⬇1.0:1.4:4.2:3.4,
synthesized in solution by using N-carboxyamino acid anhydrides
www.pnas.org兾cgi兾doi兾10.1073兾pnas.0403832101

(20). Cop1 was originally designed to induce EAE, but instead was
found to be effective in suppressing EAE (20–23) and is in current
use in the treatment of relapsing-remitting forms of MS (24–26). A
recent clinical study demonstrated its sustained efficacy in MS
patients over a period of 6 years (27). Nevertheless, Cop1 only has
a modest effect on the course of the disease. Much like IFN-␤ (28),
it reduces the relapse rate by ⬇30% in MS patients. Novel compounds with higher efficacy in the treatment of MS that take into
consideration the fact that ⬇60% of patients with MS are HLADR2 positive are needed. Additionally, the mechanism(s) by which
Cop1 performs its suppressive function remains incompletely
known (29).
Structural studies obtained from HLA-DR2兾peptide complexes
revealed that the P1 pocket of DRB1*1501 includes ␤86Val, which
results in a small pocket that can accommodate relatively small
hydrophobic amino acids such as V or F but not Y or W (30, 31).
Additionally, the residues that form the P4 pocket include ␤71Ala.
The resulting large hydrophobic pocket can accommodate F, Y, or
W, whereas the P9 pocket is promiscuous. In so far as the binding
of MBP 85–99 to HLA-DR2 is concerned, the P1 amino acid is V
and the P4 amino acid is F, although Y or W at P4 would provide
a tighter fit (30, 31). Judging from the components of Cop1, the
amino acids YEAK do not appear to fit HLA-DR2 optimally.
For the present study several random 4-aa copolymers that were
designed to bind more tightly in the key binding pockets of
HLA-DR2 were generated. Replacing Y and E with a variety of
amino acids was found to facilitate the interaction between the
resulting copolymer and the DRB1*1501 pockets and improved
binding. Among the copolymers generated, both VWAK and
FYAK [initial studies of the latter as reported (15)] had a pronounced effect in suppressing the PLP 139–151-specific T cell
response and the severity of EAE. These effects are mediated, at
least in part, by copolymer-specific, antigen-nonspecific regulatory
T cells.
Materials and Methods
Mice. SJL兾J female mice (8–10 weeks of age, The Jackson Labo-

ratory) were maintained according to the Guidelines of the Committee on Animals of Harvard University and the Committee on
Care and Use of Laboratory Animal Resources, National Research
Council (Department of Health and Human Services Publication
Abbreviations: EAE, experimental autoimmune encephalomyelitis; Cop1, Copolymer 1;
MBP, myelin basic protein; MS, multiple sclerosis; PLP, proteolipid protein; Th, T helper;
CFA, complete Freund’s adjuvant.
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85-23, revised 1987). The procedures for induction and suppression
of EAE and T cell proliferative responses in SJL兾J mice have been
described (15). Mice were scored in a double-blind manner.
Copolymers and Peptides. Copolymers and peptides were synthe-

sized as described (15). Peptide sequences were PLP 139–151,
HSLGKWLGHPDKF; hemagglutinin 306 –318, PKYVKQNTLKLAT, either unlabeled or with biotin linked to the N terminus by the spacer SGSG and free acid at the C terminus; and Nase
101–120, EALVRQGLAKVAYVYKPNNT.

Peptide Binding to I-As Protein. These studies were performed as
described (15) by using mAb Y3P to isolate I-As from LS 102.9 B
cell lines by affinity chromatography (32). Binding of biotinylated
PLP 139–151 to I-As was competed by copolymers or PLP 139–151.
Western Blot Analysis. Samples containing MHC or MHC-biotin

labeled copolymer complexes were separated on 15% SDS兾PAGE.
The gel was blotted onto poly(vinylidene difluoride) (Schleicher &
Schuell) membrane by using transblot apparatus (Bio-Rad). Membranes were blocked with 5% nonfat dry milk in TBS (0.05% Tween
20) buffer. MHC–biotin copolymer complexes were detected by
using Streptavidin POD reagent (Roche Diagnostics). I-As was
detected by using mAb Y3P and anti-mouse F(ab⬘)2-peroxidase
(Roche Diagnostics).
Cytokine Measurement by ELISA. Lymphocytes from SJL mice

immunized with PLP 139–151 with or without copolymers
(FYAK, VWAK, and Cop1) were restimulated with the corresponding peptides or copolymers in the presence of antigenpresenting cells in 24-well plates for 3 days. Briefly, cytokine
mAbs for IL-2, IL-4, IL-10, and IFN-␥ were coated to 96-well
plates at a concentration of 1 g兾ml overnight. The plates were
washed and treated with blocking solution (Kirkegaard & Perry
Laboratories), followed by incubation of cytokine standards and
culture supernatants overnight at 4°C. The plates were washed
and incubated with their corresponding biotinylated anticytokine-detecting mAb (1 g兾ml) for 2 h. They were developed
after adding avidin peroxidase and its substrate. The mAb pairs
used were from the following clones: IL-2, JES6-A112 and
JES6-5H4; IL-4, 11B11 and BVD6-24G2; IL-10, JES5-16E3 and
SXC-1; and IFN-␥, R4-6A2 and XMG 1.2 (Pharmingen).
Adoptive Transfer of CD3ⴙ Spleen Cells. Splenocytes were isolated
from SJL兾J mice immunized with either PLP139–151 and copolymers (VWAK, FYAK, or Cop1) or PLP 139–151 alone. After 24
days, a mouse T cell enrichment column (R & D Systems) was used
to isolate CD3⫹ cells. T cells (5 ⫻ 106) were injected i.v. into naı̈ve
6- to 8-week-old SJL兾J mice. The next day, mice were immunized
with PLP 139–151 peptide (50 g per mouse) as described (15) and
scored daily for signs of EAE.
Adoptive Transfer of PLP 139 –151 and Copolymer-Specific T Cell Lines.

SJL兾J mice were immunized with either 50 g of PLP 139–151
peptide or 500 g of copolymers (VWAK, FYAK, or Cop1).
Stimulator cells were prepared by loading naı̈ve SJL兾J splenocytes
in vitro for 12 h with 10 g兾ml PLP or copolymers (VWAK, FYAK,
or Cop1). Ten days postimmunization splenocytes were cocultured
with irradiated stimulators (3,000 rad) in 1:1 ratio for 5 days in T 25
flasks (1 ⫻ 108 total cells in media containing 20 units of IL-2) and
restimulated weekly for 3 weeks with fresh antigen-loaded splenocytes to obtain cell lines. T cells (5 ⫻ 106) from these lines were
injected i.v. into naı̈ve 6- to 8-week-old SJL兾J mice and the protocol
described above was followed.
Results
Amelioration of EAE by Synthetic Amino Acid Copolymers. Coimmunization of mice with PLP 139 –151 and copolymers protects against EAE.
11744 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0403832101

Fig. 1. Suppression of EAE induced with the PLP 139 –151 by different
random copolymers. Statistical analysis is shown in Table 1, which is published
as supporting information on the PNAS web site. (A) SJL兾J mice were coinjected s.c. with 50 g of PLP 139 –151 peptide and 500 g of FYAK, VWAK, or
Cop1 in CFA, or the PLP 139 –151 peptide alone, with six to eight mice in each
group. The progression of clinical signs of the disease was monitored daily.
Results represent the mean daily score. This experiment is representative of
four identical experiments with similar results. (B) SJL兾J mice were immunized
s.c. with 500 g of copolymers in CFA 2 days before administration of 50 g of
PLP 139 –151 in CFA and were observed daily for the appearance of EAE.
Results represent the mean daily score. Six to 10 mice per group were used in
each independent experiment. This experiment was carried out three times by
using preimmunization with copolymers in CFA twice and in PBS兾mannitol
once, again with similar results in all three experiments. (C) Treatment of SJL兾J
mice after induction of PLP 139 –151-induced EAE. SJL兾J mice were injected s.c.
with 50 g of PLP 139 –151 in CFA s.c. After onset of disease at a mean EAE
score of 1, 12 mice in each group (C1) or at a mean score of 1.5, 4 mice in each
group (C2) were injected s.c. on 5 consecutive days with 150 g of copolymers
in PBS兾mannitol and observed daily for the appearance of signs of EAE. Data
shown in C1 represent two separate trials of 12 mice per group. Note that
experiment (C1) was carried out with a second batch of PLP 139 –151 that was
less pure and that only 6 of 10 mice in this study died, hence the plateau in EAE
score. †, All mice died.

SJL兾J mice were immunized s.c. with 50 g of PLP 139–151 and兾or
500 g of copolymer in CFA. In the PLP 139–151-immunized
group, the first sign of EAE appeared at day 8 with a mortality of
100% (mean score, 5) by day 16 (Fig. 1A). Mice coimmunized with
Cop1 (YEAK) developed EAE beginning at day 12 with a maximal
mean score of 2.3 around day 23 followed by slow recovery by day
45. On the other hand, in mice coinjected with two copolymers,
VWAK or FYAK, essentially no disease was evident, with only one
mouse in each treatment group developing a mild disease (score of
1–2) for 10–12 days. However, two of six mice treated with two
other copolymers, FWAK and VYAK, developed severe signs of
EAE (score of 3) with no mortality and the remainder developed
a mild disease (score of 1 or 2) (data not shown); no further
Stern et al.

experiments have been carried out with these latter two copolymers. All scoring in this and the following experiments was done in
a double-blind manner.
Preimmunization with copolymers protects mice against PLP 139 –151induced EAE. SJL兾J mice were immunized s.c. with 500 g of

Treatment of PLP 139 –151-induced EAE with copolymers ameliorates
already established disease. PLP 139–151 (50 g in CFA) was injected

s.c. into SJL兾J mice. On day 11, at which time all mice had
developed mild EAE (score: 1, limp tail), 150 g of VWAK, FYAK,
or Cop1 in PBS兾mannitol per mouse was administered s.c. for 5
consecutive days. All of the copolymers suppressed further progression of EAE. VWAK- and FYAK-treated mice peaked on days
14 and 18 (maximal mean score 2, including one mortality in each
group), whereas Cop1 was less effective (score 2.5 on day 16,
including two mortalities) (Fig. 1C1). Again residual disease was
evident at 54 days after treatment with Cop1 but not with either
VWAK or FYAK. Six of nine untreated PLP 139–151-immunized
mice died but three survived, resulting in a score of 3.9.
A second treatment using only four animals per group was
initiated at a slightly later stage of EAE (score: 1.5 on day 9) (Fig.
1C2). In this experiment treatment with VWAK or FYAK (150 g
per mouse s.c. in PBS兾mannitol for 5 successive days) was less
effective (score: 2.5 or 3.0, two to three limbs paralyzed at day 14),
with only one death in the copolymer-treated group, whereas all of
the mice in the PLP 139–151-immunized group died by day 16.
Histology. Histological analysis of tissues from animals sensitized
with PLP alone showed perivascular mononuclear infiltrates typical
of EAE at all levels of the brain and spinal cord. The appearance
of these lesions in white matter tracts of the cerebellum is shown in
Fig. 5, which is published as supporting information on the PNAS
web site, and demonstrates the extensive infiltration of inflammatory cells into the CNS parenchyma, resulting in disruption of the
normal tissue architecture. In animals treated with Cop1, the
perivascular cuffs were smaller and infiltration of inflammatory
cells into the surrounding parenchyma was less marked. In animals
treated with FYAK, the lesions were even smaller, and lesions were
detected only rarely at this site in animals treated with VWAK.
Analysis of myelin loss, using immunhistochemical staining for
MBP, showed that the extent of demyelination was well correlated
with the extent of the inflammatory infiltrates, with large demyelinated plaques centered around blood vessels evident in the PLP
controls, medium plaques in Cop1-treated mice, much smaller
plaques in animals treated with FYAK, and well-preserved myelin
in animals treated with VWAK.
Mechanism of Suppression of PLP 139 –151-Induced EAE by Copolymers. Blocking of binding of PLP 139 –151 to I-As molecules by copolymers.

To investigate whether various copolymers inhibited binding of PLP
139–151 to purified I-As, binding assays and confocal microscopy
were performed. With biotinylated PLP 139–151 all of the copolymers were shown to compete for its binding to I-As (Fig. 2A).
However, VWAK was significantly better than Cop1 or FYAK in
competing with the biotinylated peptide (Fig. 2B), particularly at
low concentrations. Confocal microscopy was also used to show that
Stern et al.

Fig. 2. Inhibition of binding of biotinylated PLP 139 –151 to I-As molecules by
different competitors. (A) I-As (100 M) isolated from LS102.9 cells was incubated with biotinylated peptides or copolymers (1 mM) for 48 h at 37C in PBS
(30 l total volume). Samples containing 15 l of the mixture were separated
on 15% SDS兾PAGE. The gel was blotted onto a poly(vinylidene difluoride)
membrane. I-As protein was detected by using mAb 10.3.6 and horseradish
peroxidase (HRP)-conjugated anti-mouse IgG (lane 1). Peptide and copolymer
complexes were detected with streptavidin HRP by using standard blotting
and ECL detection techniques (lanes 2–7). (B) I-As molecules were incubated
with biotinylated PLP 139 –151 (0.13 M, }) and the unlabeled copolymers
(FYAK, 䊐; Cop-1, {; and VWAK, ‚) at a range of concentrations. All incubations were carried out in triplicate at pH 7.0 for 40 h at 37°C. Results represent
one of three independent experiments. Specific binding is expressed as percentage of inhibition by using the formula: percentage of inhibition ⫽ 100%
⫺ [(absorbance at 450 nm with competitor ⫺ background)兾(absorbance without competitor ⫺ background) ⫻ 100]. The signals at 450 nm without competitor was from 0.910 to 1.04, and the background was 0.08.

I-As and copolymers colocalized on the surface of bone marrowderived murine dendritic cells (Fig. 6, which is published as supporting information on the PNAS web site).
Suppression by copolymers of PLP-specific T cell proliferation. SJL兾J mice
were immunized with 50 g of PLP 139–151 in CFA alone or
coimmunized with PLP and 500 g of copolymers s.c. On day 10
splenocytes (that contain both T cells and antigen-presenting cells)
from mice immunized with PLP 139–151 responded vigorously to
the antigen in vitro, as expected, whereas little proliferation to PLP
139–151 was seen after immunization with the irrelevant peptide
Nase (Fig. 3A1). However, when splenocytes from mice coimmunized with copolymers were restimulated with PLP 139–151, expansion of PLP 139–151-reactive T cells in splenocytes was suppressed; VWAK had the most pronounced effect followed by Cop1
and FYAK (Fig. 3A2).
Cell lines responsive to either PLP 139–151 or individual copolymers were then established by restimulation of splenocytes pulsed
with the individual antigens alone over a period of 3 weeks (Fig.
3B1). The PLP 139–151-specific cell line did not react to any of the
copolymers (Fig. 3B2). Likewise, PLP 139–151 did not stimulate
any of the copolymer-specific T cell lines (Fig. 3B3), and no
cross-stimulation by copolymers was observed (data not shown).
Thus, no cross-reactivity between PLP 139–151 and copolymerspecific cell lines was observed and each of the copolymer-specific
cell lines was specific for the copolymer used in immunization and
restimulation.
Blocking by copolymers of PLP-specific T cell expansion in vitro. To
determine the frequency of PLP-responsive T cells in spleen,
I-As兾PLP 139–151 tetramers were used. The percent PLP 139–
151-reactive CD4 T cells in splenocytes was determined by flow
cytometric analysis using Theiler’s murine encephalomyelitis virus
(TMEV) 70–86 tetramers as negative controls (32–34). Splenic
lymphocytes from PLP 139–151-immunized mice were cultured
with PLP 139–151 with or without copolymers for 4 days. The
CD4⫹CD25⫹-activated T cell population was gated after eliminating dead cells. The I-As tetramer-positive cells within this CD4
subset were then determined (Fig. 7A, which is published as
supporting information on the PNAS web site). After restimulation,
PNAS 兩 August 10, 2004 兩 vol. 101 兩 no. 32 兩 11745
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copolymer either in complete Freund’s adjuvant (CFA) or PBS, 2
days before administration of 50 g of PLP 139–151 in CFA (Fig.
1B). Copolymer in PBS or CFA yielded essentially identical data.
All control mice immunized with PLP 139–151 developed severe
EAE with a mortality of 100%. On the contrary, preinjection on day
2 with VWAK, FYAK, or Cop1 reduced the clinical signs of PLP
139–151-induced EAE. VWAK and FYAK reduced the intensity
and duration of EAE with maximal mean scores of 1.9 and 2.8 on
day 16, respectively, whereas Cop1-treated mice had a maximal
mean score of 3.8 (Fig. 1B). Thus, in this assay VWAK was
significantly more effective than the other copolymers. Residual
disease was also significantly greater at day 64 with Cop1 than with
either VWAK or FYAK. Preimmunization with copolymers 4 days
before inducing the disease gave similar results (data not shown).

Cytokine production by splenocytes after coimmunization with copolymers
and PLP 139 –151. Cytokine profiles were determined by ELISA in

splenocyte cultures derived from SJL兾J mice immunized with PLP
139–151 with or without copolymers and restimulated in vitro with
PLP 139–151 or copolymers. CD4 T cells from PLP 139–151immunized mice produce IFN-␥, but not IL-4 or IL-10, upon in vitro
activation with PLP 139–151. Splenocytes from mice coimmunized
with PLP 139–151 and copolymers continued to produced INF-␥.
In addition, IL-4 and IL-10 both were produced by splenocytes from
coimmunized mice on copolymer stimulation (presumably by copolymer-specific T cells, see below) (Fig. 8, which is published as
supporting information on the PNAS web site).
Lack of anergy induction by copolymers. See Fig. 9, which is published
as supporting information on the PNAS web site.
Suppression by adoptive transfer of CD3ⴙ T splenocytes from mice
coimmunized with PLP 139 –151 and copolymers. SJL兾J mice were

Fig. 3. Stimulation of splenocytes and T cell lines by PLP 139 –151 or copolymers. (A) SJL mice were immunized with either PLP 139 –151 in CFA (A1) or
coimmunized with copolymers (A2). After 10 days, splenocytes were cultured
for 3 days with PLP 139 –151 alone (}) or Nase peptide (used as a control) (■).
Sixteen hours after pulsing with 3H-thymidine, the proliferative response was
measured as radioactivity incorporated. (B) SJL兾J mice were immunized with
either PLP 139 –151 (}) or copolymers, VWAK (‚, FYAK (䊐), and Cop1, ({) in
CFA. After 10 days, splenocytes were restimulated with either PLP 139 –151 or
copolymers biweekly three times, and the proliferative response was determined as above to each of the four antigens of the homologous cell lines (B1),
each of the copolymers or Nase of the PLP-specific cell line (B2), or PLP 139 –151
of each of the copolymer-specific cell lines (B3).

splenocytes from mice immunized with PLP 139–151 alone had
4.61% PLP 139–151 tetramer⫹ CD4⫹ cells. No PLP 139–151reactive CD4⫹ T cells were detected in mice immunized with only
CFA. When cells from PLP 139–151-immunized mice were restimulated in vitro with both PLP 139–151 and copolymers, the frequency of PLP 139–151-reactive T cells was decreased in all three
groups, Cop1 (4.01%), FYAK (3.34%), and VWAK (2.92%; P ⬍
0.05). TMEV 70–86 tetramer-stained cells were negligible in all
groups. The suppressive effect on the antigen-specific response to
PLP 139–151 by copolymers in vitro was maximum for VWAK.
Although this decrease may not seem large, it amounts to a 37%
decrease in total number of PLP 139–151-reactive cells. Thus,
coactivation with copolymers can suppress expansion of antigenspecific T cells.
The question of whether coimmunization of mice with copolymers and PLP 139–151 altered the expansion of PLP-specific T cells
in vivo was examined after in vitro expansion (because their
frequency ex vivo is too low to measure by tetramer staining without
in vitro expansion). The effect of coimmunization with copolymers
was remarkably similar to the effect observed on addition of
copolymers in vitro. The PLP 139–151-reactive T cell expansion in
cultures stimulated with PLP 139–151 was consistently reduced in
all of the groups as compared with the mice immunized with only
PLP 139–151 (maximum reduction, 37%) (Fig. 7). In contrast, no
expansion of PLP 139–151-reactive T cells was observed in cultures
treated only with copolymers, again supporting the lack of crossreactivity.
11746 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0403832101

immunized with PLP 139–151 in CFA alone or coimmunized with
Cop1, VWAK, or FYAK together with PLP 139–151. Only mice
immunized with PLP 139–151 with or without Cop1 developed
mild or severe EAE symptoms with scores of 1.7 and 2.8, respectively on day 24. As expected, no disease appeared in mice
coimmunized with PLP 139–151 and either VWAK or FYAK (Fig.
4A1). On day 24, CD3⫹ splenocytes (5 ⫻ 106) from each of the
coimmunized mice were transferred into naı̈ve SJL mice. The next
day they were immunized s.c. with 50 g of PLP 139–151 in CFA.
Mice into which CD3⫹ splenocytes from PLP 139 –151immunized mice had been transferred developed disease with onset
on day 8 and a maximal mean score of 4, about the same as PLP
139–151-immunized mice that had not received any adoptive
splenocytes. Mice into which splenocytes from VWAK- or FYAKcoimmunized animals were transferred had scores of 1.6 and 2.2,
respectively, both with an onset on day 10, and essentially no disease
by day 40 (Fig. 4A2). By contrast CD3⫹ splenocytes from Cop1treated mice had a score of 3 on day 18 and appeared to stabilize
with a score of 1.5 by day 30. Thus, CD3⫹ splenocytes generated
after VWAK or FYAK, and to a lesser extent after Cop1 treatment,
had significantly suppressed PLP 139–151-induced EAE. Residual
disease at day 58 was present when using CD3⫹ splenocytes from
Cop1-treated mice but not from YFAK- or VWAK-treated mice.
Suppression by adoptive transfer of copolymer-specific T cell lines. SJL兾J
mice were immunized s.c. with either 50 g of PLP 139–151 or 500
g of copolymer. On day 10, splenocytes were restimulated three
times in vitro every other week with peptide- or copolymer-pulsed
irradiated splenocytes from naı̈ve mice. After the third round of
stimulation, 5 ⫻ 106 T cells of each copolymer- or PLP 139–151stimulated population were administered i.v. into each mouse. The
disease was induced the next day by using PLP 139–151 in CFA as
described in Materials and Methods. Compared to PLP 139–151
controls all of the mice that received copolymer-specific T cells had
a delayed onset of a much milder form of EAE (Fig. 4B).
Cytokine profiles were determined by ELISA in splenocyte
cultures derived from SJL兾J mice immunized with either PLP
139–151 or copolymers and restimulated in vitro with the respective
antigen. Previously, splenocytes from PLP 139–151-immunized
mice produced IFN-␥ but not IL-4 or IL-10 upon in vitro activation
with PLP 139–151 (Fig. 8). Splenocytes from these PLP 139–151immunized mice were restimulated three times biweekly to establish lines. These PLP 139–151-specific lines produced all of these
cytokines (Fig. 4C). Interestingly, similar lines established with
copolymers did not produce the Th1 cytokines IFN-␥ and IL-2
although they produced the Th2 cytokines IL-4 and IL-10 (Fig. 4C).
The T cell lines used for transfer were in all cases ⬇90% CD4⫹ T
cells (Fig. 4D).
Discussion
In this study, the copolymers FYAK and VWAK, which were
designed based on the amino acid residues responsible for binding
of MBP 85–99 and the peptide binding pockets of HLA-DR2 (30,
Stern et al.

31), effectively suppressed the severity of PLP 139–151-induced
EAE in SJL兾J (I-As) mice (Fig. 1) that was paralleled by evidence
of reduction of disease severity or disease elimination as seen by
histochemical staining (Fig. 5). MBP 85–99 interacts with the
HLA-DR2 (DRB1*1501) molecule to which MS is linked, and for
this reason the copolymers were primarily designed to bind to
HLA-DR2 molecules. Importantly, these copolymers were shown
to bind also to I-As, the only class II MHC protein expressed in
SJL兾J mice and to cluster with and compete with PLP 139–151 for
binding to I-As (Figs. 2 and 6). Previously, aggregates (clusters) of
Stern et al.
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Fig. 4. Suppression of EAE upon adoptive transfer of either CD3⫹ T cells from
coimmunized SJL兾J mice or copolymer-specific T cell lines from copolymerimmunized SJL兾J mice. Statistical analysis is shown in Table 1. (A1) SJL兾J mice
were injected with 50 g of PLP 139 –151 in CFA with or without 500 g of
copolymer s.c. After disease induction, mice were observed daily for the
appearance of signs of EAE. (A2) Splenocytes (5 ⫻ 106) from mice immunized
s.c. with 50 g of PLP 139 –151 in CFA only (}), without prior immunization for
comparison (F), or mice coimmunized s.c. with PLP 139 –151 and 500 g of
copolymer (VWAK, 䊐; FYAK, 䊐; or Cop1, {) were transferred on day 24 of the
experiment in A1 into naı̈ve SJL兾J mice. The next day, the mice were immunized s.c. with 50 g of PLP 139 –151 in CFA. Mice were observed daily for the
appearance of signs of EAE. This is one of two nearly identical independent
experiments. (B) Copolymer-specific or PLP 139 –151-specific T cells (5 ⫻ 106)
from lines established after immunization with either copolymers or PLP
139 –151 were transferred into naı̈ve SJL兾J mice, and the next day the mice
were immunized s.c. with 50 g of PLP 139 –151 in CFA. (C) Cytokine secretion.
The culture supernatants of the above lines were examined for cytokine
production by ELISA. (D) Fluorescence-activated cell sorting analysis of copolymer-specific T cell lines.

I-As molecules after Cop1 binding were detected on the surface of
antigen-presenting cells from SJL兾J mice (35). FYAK and VWAK
were more potent than Cop1 in binding to mouse I-As molecules
and in competing for PLP 139–151 binding. Their efficacy in vivo
in SJL兾J mice with PLP 139–151-induced EAE was examined by
using three protocols: (i) preimmunization of mice with copolymers
before the induction of EAE by PLP 139–151 (vaccination); (ii)
coimmunization of mice with copolymers and PLP 139–151 together (prevention); and (iii) treatment of mice with copolymers
after onset of EAE induced by PLP 139–151 (therapy). In all of
these protocols, the copolymers showed a pronounced suppressive
effect on PLP 139–151-induced EAE in the order VWAK ⬎ FYAK
⬎⬎ Cop1.
The mechanism by which the copolymers exert their effects was
examined in several protocols in addition to the binding assay. First,
the copolymers were inhibitors of the expansion of PLP 139–151specific T cells (proliferation assays), both in vitro and in vivo, again
in the order VWAK ⬎ FYAK ⬎ Cop1 (Figs. 3 and 7).
Second, copolymers shifted the T cell immune response from a
classical Th1 phenotype toward a Th2 response (immune deviation). EAE induced by myelin antigens such as MBP and PLP
139–151 are regarded as Th1 cell-mediated diseases, although Th2
cells have been shown to induce EAE under certain conditions (36).
In SJL兾J mice, restimulation of splenocytes from PLP 139–151immunized animals with PLP 139–151 in vitro induced the production of IFN-␥ but not IL-4 or IL-10 (Fig. 8). However, splenocytes from mice coimmunized with PLP 139–151 and copolymers
when restimulated with their corresponding copolymers also produced IL-4 and IL-10 without much alteration in the production of
IFN-␥. The Th2 cytokines, IL-4 and IL-10, have antiinflammatory
properties (10, 11, 37). Furthermore, B6 mice transgenic for IL-4 or
IL-10 are resistant to myelin oligodendrocyte glycoprotein 35–55induced EAE (10, 11) and hence these cytokines may play a critical
role in reducing the severity of inflammatory diseases such as EAE.
These cytokines may be produced by copolymer-specific T cells (see
below) with a negligible contribution, if any, from PLP 139–151reactive T cells.
Third, copolymers may mediate their effects by inducing copolymer-specific T cells with the Th2 phenotype (38). The copolymers
upon immunization of SJL兾J mice induced a copolymer-specific T
cell response (Fig. 3), i.e., the copolymers are immunogenic.
Moreover, adoptive transfer of copolymer-specific T cells reduced
markedly the severity of EAE (Fig. 4), suggesting that they produce
Th2 cytokines without copolymer restimulation. How then do the
copolymer-specific T cells regulate autoantigen-reactive T cells in
vivo? Do the copolymer-specific T cells work in a manner similar to
CD4⫹CD25⫹ T cells, which have been shown to prevent the
occurrence of several autoimmune diseases including EAE (39, 40),
or by secretion of Th2 cytokines? Further clarification is required.
Moreover, the copolymer- specific T cell lines are antigen nonspecific, i.e., they can be generated and they respond to copolymers in
the absence of antigen (Figs. 3 and 4). Thus, they may be useful in
the treatment of other autoimmune diseases or in those where
several autoantigens are involved, as is likely to be the case in MS.
However, whatever the mechanism, the first step must be binding
to a class II MHC protein (41, 42). The copolymers were optimized
for binding to HLA-DR2 but they are likely to bind promiscuously
to class II MHC proteins with varying affinities (41). They obviously
bind to I-As with high affinity (Fig. 3B). A number of mechanisms
in addition to blocking and immune deviation resulting from the
generation of copolymer-specific T cells, such as T cell antigen
receptor competition (43, 44) or induction of anergy (45), may be
operative. Induction of hyporesponsive T cells (anergy) in MS
patients after continuous administration of Cop1 has been observed (45). The generation of copolymer-specific CD4⫹ Th2 cell
lines that secrete IL-4 and IL-10 and can adoptively transfer
resistance to EAE appears very prominent among these mecha-

induce T cell anergy much more efficiently than FYAK in the
humanized double-transgenic mouse model, although in the
present work in H-2s mice no anergy induction by either copolymer
was observed (Fig. 9). Conversely VWAK induces IL-4 and IL-10
production only relatively weakly and, like FYAK, also induces T
cell anergy relatively poorly. Thus, a combination of mechanisms
may be involved in the reduction of severity of EAE and perhaps
a combination of copolymers would be the most effective treatment
of EAE and by extension of MS.

nisms. Copolymers might also suppress disease through modulating
CNS antigen-presenting cells i.e., microglia.
Different copolymers may have different mechanisms of suppression. VWAK appears to be less able to generate T cell lines
(Fig. 3 B1) and also generates larger amounts of IL-4 and lower
amounts of IFN-␥ (Fig. 8). Yet it suppresses EAE somewhat more
effectively (Fig. 1). However, VWAK binds more tightly to I-As and
may be a better blocking agent. In an accompanying paper (46), the
efficacy of these copolymers has also been tested in a humanized
double-transgenic mouse model expressing human HLA-DR2
(DRB1*1501) and a human T cell antigen receptor specific for
MBP 85–99 from an MS patient and their mechanisms were
compared. Although the mechanisms are similar, some differences
were observed.
What accounts for the slightly greater effectiveness of VWAK
than FYAK? FYAK is much more effective in stimulating copolymer-specific T cell lines and production of antiinflammatory cytokines IL-4 and IL-10, and thus should be much more effective in
disease reduction if immune deviation is the mechanism. On the
other hand, in an accompanying paper (48), VWAK is shown to
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